A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Although Pfizer has made some efforts to turn things around, they have been insufficient. Pfizer's poor performance since ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, ...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to ...

The updated warnings highlight a rare risk of heart inflammation in teen boys and young men, CBS News reported. The warning ...

This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more ...